Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16
NCT03164967
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Humoral Immune Response
Interventions
BIOLOGICAL:
Bivigam
Sponsor
ADMA Biologics, Inc.